Alaunos Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Alaunos Therapeutics faces severe financial distress with cash plummeting 74% to just $354k, operating losses of $1M quarterly, and no revenue generation. The company issued preferred stock and equity for services, indicating desperate funding measures. With minimal cash reserves and continued burn rate, the company faces imminent going concern issues.
Red Flags Detected (7)
Cash and cash equivalents crashed 74% from $1.385M to $354k in just 3 months
No revenue generation ($0 vs $2k prior year)
Continued operating losses of $1M per quarter with $1.01M burn rate
4 more red flags detected
Key Takeaways
Company has approximately 3-4 months of cash remaining at current burn rate
No revenue generation in biotech company indicates lack of commercialized products
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.